Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. by Parikh, Sunil et al.
Parikh, Sunil; Kajubi, Richard; Huang, Liusheng; Ssebuliba, Joshua;
Kiconco, Sylvia; Gao, Qin; Li, Fangyong; Were, Moses; Kakuru,
Abel; Achan, Jane; Mwebaza, Norah; Aweeka, Francesca T (2016)
Antiretroviral Choice for HIV Impacts Antimalarial Exposure and
Treatment Outcomes in Ugandan Children. CLINICAL INFECTIOUS
DISEASES, 63 (3). pp. 414-422. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/ciw291
Downloaded from: http://researchonline.lshtm.ac.uk/4651987/
DOI: 10.1093/cid/ciw291
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Clinical Infectious Diseases
M A J O R A R T I C L E
HIV/AIDS
Antiretroviral Choice for HIV Impacts Antimalarial
Exposure and Treatment Outcomes in Ugandan Children
Sunil Parikh,1 Richard Kajubi,2 Liusheng Huang,3 Joshua Ssebuliba,2 Sylvia Kiconco,2 Qin Gao,3 Fangyong Li,3 Moses Were,2 Abel Kakuru,2 Jane Achan,2
Norah Mwebaza,2 and Francesca T. Aweeka3
1Yale School of Public Health, New Haven, Connecticut; 2Makerere University College of Health Sciences, Kampala, Uganda; and 3University of California, San Francisco, and San Francisco General Hospital
(See the Editorial Commentary by Fehintola, Adedeji, and Morse on pages 423–4.)
Background. The optimal treatment of malaria in human immunodeﬁciency virus (HIV)–infected children requires consider-
ation of critical drug–drug interactions in coinfected children, as these may signiﬁcantly impact drug exposure and clinical outcomes.
Methods. We conducted an intensive and sparse pharmacokinetic/pharmacodynamic study in Uganda of the most widely
adopted artemisinin-based combination therapy, artemether-lumefantrine. HIV-infected children on 3 different ﬁrst-line antiretro-
viral therapy (ART) regimens were compared to HIV-uninfected children not on ART, all of whom required treatment for Plasmo-
dium falciparum malaria. Pharmacokinetic sampling for artemether, dihydroartemisinin, and lumefantrine exposure was conducted
through day 21, and associations between drug exposure and outcomes through day 42 were investigated.
Results. One hundred forty-ﬁve and 225 children were included in the intensive and sparse pharmacokinetic analyses, respec-
tively. Compared with no ART, efavirenz (EFV) reduced exposure to all antimalarial components by 2.1- to 3.4-fold; lopinavir/
ritonavir (LPV/r) increased lumefantrine exposure by 2.1-fold; and nevirapine reduced artemether exposure only. Day 7 concentra-
tions of lumefantrine were 10-fold lower in children on EFV vs LPV/r-based ART, changes that were associated with an approximate
4-fold higher odds of recurrent malaria by day 28 in those on EFV vs LPV/r-based ART.
Conclusions. The choice of ART in children living in a malaria-endemic region has highly signiﬁcant impacts on the pharmacoki-
netics and pharmacodynamics of artemether-lumefantrine treatment. EFV-based ART reduces all antimalarial components and is asso-
ciated with the highest risk of recurrent malaria following treatment. For those on EFV, close clinical follow-up for recurrent malaria
following artemether-lumefantrine treatment, along with the study ofmodiﬁed dosing regimens that provide higher exposure, is warranted.
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Malaria and human immunodeﬁciency virus infection (HIV)
impose extensive and overlapping burdens in sub-Saharan
Africa. The World Health Organization (WHO) estimated
198 million malaria cases and 584 000 malaria-related deaths
in 2013, with 90% occurring in sub-Saharan Africa [1]. Al-
though malaria deaths have declined, a substantial burden
remains [1], reﬂected in malaria infection rates of up to 6 epi-
sodes per person year in HIV-uninfected children in Eastern
Uganda [2–4].
Sub-Saharan Africa is also home to 25 million people with
HIV [5, 6]; 2.9 million are children aged <15 years [6]. Access
to antiretroviral therapy (ART) has expanded, and the WHO
recommends that all children receive ART [7, 8]. Currently, a
lopinavir/ritonavir (LPV/r)–based regimen is recommended
as ﬁrst-line in children <3 years, or, if this is not feasible, a ne-
virapine (NVP)–based regimen [9]. For children aged ≥3 years,
including adolescents, efavirenz (EFV) is preferred, and NVP is
the alternative [9]. Despite reduced mother-to-child transmis-
sion, an estimated 2 million HIV-infected children will reside
in sub-Saharan Africa in 2020 [8].
Optimally treating malaria and HIV in children requires con-
sideration of complex biological and pharmacological factors
that impact artemisinin-based combination therapy (ACT). De-
velopmental changes in pharmacokinetics in children are often
ignored, and concomitant ACT and ART results in drug–drug
interactions that may have signiﬁcant treatment effects. HIV in-
fection impairs antimalarial immunity, and if untreated, in-
creases malaria morbidity and mortality [10]. In addition, use
of trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis
further impacts one’s risk of malaria [11]. Overlooking these
factors places children at greater risk of poor treatment out-
comes, including increasing rates of reinfection in highly en-
demic regions, and of greater concern, the potential for
treatment failure and ACT resistance [1, 4, 12, 13].
ACTs are adopted in 79 of 88 Plasmodium falciparum–
endemic countries [1]. ACTs combine a short-acting artemisinin
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that rapidly reduces parasite load, with a long-acting partner drug
that eradicates parasites and helps prevent new infections, mini-
mizing the emergence and spread of resistance. Artemether-
lumefantrine is the most widely used ACT, and is metabolized
by cytochrome P450 (CYP), including CYP3A4/2B6 for arte-
mether (converted to the active metabolite dihydroartemisinin
[DHA]) [14] and CYP3A4 for lumefantrine [15]; thus, both are
susceptible to CYP inhibition/induction with ART.
Our group previously reported that the incidence of recurrent
malaria following artemether-lumefantrine in HIV-infected
children was lower in children on LPV/r- vs nonnucleoside
reverse transcriptase inhibitor (NNRTI)–based ART [4]. We
now report results from a large intensive pharmacokinetic/
pharmacodynamic (PK/PD) study, aimed at fully delineating
the pharmacological basis of these differences. The PK/PD of
artemether-lumefantrine for treatment of malaria in HIV-
infected children stabilized on 3 ﬁrst-line ART regimens were
compared both between ART regimens and to concurrently
enrolled HIV-uninfected children, with the goal of informing
artemether-lumefantrine treatment guidelines.
METHODS
Study Area and Patients
This prospective PK/PD study of artemether-lumefantrine for
the treatment of uncomplicated malaria in HIV-infected
children and HIV-uninfected children was conducted from
5 August 2011 to 5 November 2014 in the high-transmission-
intensity district of Tororo, Uganda. Children aged 0.5–8
years were enrolled if eligibility criteria were met (Supplemen-
tary Data). HIV-infected children were typically on standard
weight-based-dosed lamivudine and zidovudine with either
LPV/r, or the NNRTIs NVP or EFV, and 96% were on daily
TMP-SMX prophylaxis [9].
Clinical Management and Pharmacokinetic Methods
Children enrolled had uncomplicated P. falciparum malaria
conﬁrmed by thick blood smear (regardless of parasite density),
and documented or 24-hour fever history (≥38.0°C). Active fol-
low-up occurred on days 0 (diagnosis) through 28, with passive
follow-up to day 42. Recurrent malaria episodes were genotyped
to distinguish recrudescent from new infections [16].
A standard 6-dose treatment of weight-based artemether-
lumefantrine (Coartem Dispersible 20 mg/120 mg, Novartis
Pharma AG, Basel, Switzerland) was administered with milk
or breastfeeding in the clinic or at home, to enhance and control
for lumefantrine absorption [17]. For the intensive PK cohort,
sampling was pre–ﬁrst dose (day 0) and pre/post–sixth dose
(7 venous samples on day 3 at 0, 0.5, 1, 2, 3, 4, and 8 hours
post–last dose), and days 4, 7, 14, and 21 (capillary) (Supple-
mentary Data). For the sparse PK cohort, lumefantrine capillary
sampling occurred on days 7, 14, and 21. Concentrations of ar-
temether, DHA, and lumefantrine were determined using liquid
chromatography–tandem mass spectrometry, as previously de-
scribed [18, 19]. For artemether and DHA, the calibration range
was 0.5–200 ng/mL, the lower limit of quantiﬁcation (LLOQ)
was 0.5 ng/mL [18], and the coefﬁcient of variation (CV%) was
<10% for each analyte. For lumefantrine, calibration range was
50–20 000 ng/mL, LLOQ was 50 ng/mL, and CV% was <5%
[19]. Primary outcome was plasma PK parameters for arte-
mether, DHA, and lumefantrine. For intensive studies, this in-
cluded the area under the concentration-time curve (AUC0–8
hours for artemether and DHA; AUC0-∞ for lumefantrine), max-
imal concentration (Cmax), time to Cmax (Tmax), elimination
half-life (T1/2), DHA/artemether AUC ratio, C24h (artemether),
and C8h (DHA). Noncompartmental analysis was utilized (Sup-
plementary Data).
Treatment Outcomes
Secondary safety and tolerability including adverse events were
assessed using National Institute of Allergy and Infectious Dis-
eases Division of AIDS criteria [20]. Secondary treatment out-
comes included polymerase chain reaction–unadjusted/
adjusted recurrent malaria at 28 and 42 days using standard
WHO criteria (Table 4; Supplementary Data) [21]. Gametocy-
temia was assessed on day 0 and each day of follow-up.
Statistical Analysis
For intensive PK, it was necessary to use 30 subjects for each
ART regimen to detect a 35% AUC difference of all analytes
(80% power; α = .05). Data were presented as geometric mean
(GM) or median (range) as appropriate. A mixed-models
repeated-measures analysis was performed for group compari-
sons. Odds of recurrent malaria were assessed using generalized
estimating equations (GEEs) with covariate adjustment for age,
parasite density, hemoglobin, sex, and lumefantrine exposure.
Mediation analysis was performed to investigate whether asso-
ciations between treatment regimens and outcomes were trans-
mitted by lumefantrine exposure, using Sobel test on the
product of coefﬁcients for the mediation effect [22]. Mediation
was presented as the proportion of the effect of the regimen (ex-
posure) on the outcome that acts through the path of the drug
concentration (mediator). Risk of recurrent malaria was analyzed
using proportional Cox regression with robust sandwich estima-
tor that accounts for repeated episodes adjusted for above covar-
iates. Statistical signiﬁcance was a 2-sided P value < .05, except for
PK parameter pairwise group comparisons where Bonferroni
correction was used. Stata version SE12.1 (StataCorp, College
Station, Texas) and SAS version 9.4 (SAS Institute, Cary, North
Carolina) software programs were used for analyses.
RESULTS
Study Proﬁle
Participants were enrolled into intensive or sparse PK cohorts
(Table 1; Supplementary Figure 1). Cohorts were combined
for analyses except for intensive PK parameters, as speciﬁed.
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For the intensive cohort, children were screened for enrollment
over the course of 219 episodes of malaria; 166 met enrollment
criteria, and 145 were included in the ﬁnal PK/PD analysis
(54 HIV-uninfected/91 HIV-infected children). For the sparse
PK cohort, children were screened over the course of 448 epi-
sodes of malaria; 232 were eligible, with 225 included in the
ﬁnal analysis (134 HIV-uninfected/91 HIV-uninfected chil-
dren). Children were eligible for enrollment for a single episode
of intensive PK sampling, and multiple episodes of sparse PK
sampling. Parasite densities were comparable between ART
groups, but lower in LPV/r-treated vs HIV-uninfected children
(GM, 6917 vs 16 189 parasites/µL; P = .002). Baseline gametocy-
temia was higher in children on EFV (22.0%) than in those on
LPV/r (7.1%) (P = .03).
Pharmacokinetics of Artemether and DHA
Pharmacokinetic parameters for the intensive cohort are
summarized in Table 2 and Figure 1. Compared to results for
HIV-uninfected children, both NNRTIs signiﬁcantly reduced ar-
temether Cmax and AUC0–8h (2.3- and 2.5-fold, respectively, for
Table 1. Demographics of Study Participants
Variable HIV-Uninfected
HIV-Infected
EFV-Based ART LPV/r-Based ART NVP-Based ART
Total episodes, No. 188 182
Intensive PK sampling episodes (n = 145) 54 31 30 30
Sparse PK sampling episodes (n = 225) 134 19 40 32
Age, y, median (range) 3.5 (1.1–7.9) 5.6 (3.1–8.6) 4.6 (1.4–8.0) 4.6 (1.4–8.0)
Weight, kg, median (range) 13.8 (9.8–27) 17.6 (11.4–25.1) 15.1 (7.7–23.7) 16.3 (8.5–30.0)
Parasite density at diagnosis, geometric mean µL−1 (95% CI)a 16 189 (12 042–21 763) 11 671 (6389–21 321) 6917 (3839–12 463) 10 568 (5746–19 435)
Gametocytes present at diagnosisb 11.2% 22.0% 7.1% 14.8%
Gametocytes present at any point from day 1 to 28c 17.0% 36.0% 20.0% 29.6%
Hemoglobin at diagnosis, g/dL, median (IQR) 10.8 (9.7–11.4) 10.5 (9.7–11.3)
Total lumefantrine dose, mg/kg, median (range) 65.4 (48.3–96.0) 74.0 (48.3–96.4)
Total artemether dose, mg/kg, median (range) 10.9 (8.1–16.0) 12.3 (8.1–16.1)
There were no differences in demographic parameters between the intensive and sparse PK sampling cohorts.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; HIV, human immunodeficiency virus; IQR, interquartile range; LPV/r, lopinavir/ritonavir; NVP, nevirapine;
PK, pharmacokinetic.
a Geometric mean parasite density on the day of diagnosis was significantly different in those on LPV/r vs HIV-uninfected children (P = .002; adjusted for repeated measures); differences not
significant for other group comparisons.
b P = .032 for gametocytemia on the day of diagnosis in those on EFV- vs LPV/r-based ART; adjusted for repeated measures.
c Gametocytemia newly developing on days 1–28 was significantly more common in both children on EFV- or NVP-based ART compared with HIV-uninfected children (P = .008; adjusted for
repeated measures).
Table 2. Artemisinin Pharmacokinetics Following a 6-Dose Regimen of Artemether-Lumefantrine in Human Immunodeficiency Virus (HIV)-Uninfected and
HIV-Infected Children
Pharmacokinetic Parameter
HIV-Uninfected HIV-Infected Ratio (P Value)
No ART (n = 51a) EFV (n = 31) LPV/r (n = 30b) NVP (n = 30) EFV/No ART LPV/No ART NVP/No ART
Artemether
Cmax, ng/mL 35.3 (28.0–44.5) 15.3 (11.2–21.1) 26.4 (19.1–36.4) 10.2 (7.6–13.8) 0.43 (.0006) 0.75 (.23) 0.29 (<.0001)
Tmax, h 2.0 (.7–3.0) 2.1 (1.1–4.0) 3.0 (1.1–4.0) 2.1 (1.1–3.1) 1.1 (.22) 1.5 (.18) 1.1 (.29)
AUC0–8h, h × ng/mL 120 (97.6–147) 48.5 (37.2–63.1) 89.7 (68.6–117) 36.3 (27.8–47.4)
c 0.40 (<.0001) 0.75 (.16) 0.30 (<.0001)
C24h, ng/mL 1.2 (.7–1.7) BLQ (BLQ–.8) 1.2 (.6–2.5) BLQ (BLQ–1.1) <1 (<.0001) 0.98 (.96) <1 (<.0001)
DHA
Cmax, ng/mL 66.9 (53.6–83.5) 24.0 (18.0–32.0) 55.3 (41.3–74.1) 45.5 (34.1–60.8) 0.36 (<.0001) 0.83 (.39) 0.68 (.08)
Tmax, h 2.9 (2.0–3.1) 3.0 (1.1–4.0) 3.0 (2.0–4.1) 2.2 (2.0–4.0) 1.0 (.75) 1.0 (.99) 0.80 (.31)
AUC0–8h, h × ng/mL 212 (176–256) 62.9 (49.2–80.3)
c 171 (133–219) 137 (107–175) 0.30 (<.0001) 0.81 (.25) 0.65 (.02)
C8h, ng/mL 6.5 (4.6–8.0) 1.2 (.6–3.4) 9.3 (4.6–16.5) 4.5 (2.9–8.8) 0.19 (<.0001) 1.42 (.16) 0.681 (.41)
AUC ratio (DHA/AR) 1.7 (1.3–2.5) 1.6 (.8–2.2) 1.9 (1.5–3.4) 4.1 (2.2–6.9) 0.94 (.07) 1.12 (.74) 2.41 (<.0001)
Data are presented as geometric mean (90% confidence interval) unless otherwise specified. Significance level: α = .0083 (0.05/6); Tmax, C8h, and C24h reported as median (interquartile range);
mixed-models repeated-measures analysis to compare between all groups using log-transformed geometric means.
Abbreviations: AR, artemether; ART, antiretroviral therapy; AUC, area under the concentration-time curve; BLQ, below the limit of quantitation; Cmax, maximal concentration; DHA,
dihydroartemisinin; EFV, efavirenz; HIV, human immunodeficiency virus; LPV, lopinavir; NVP, nevirapine; r, ritonavir; Tmax, time to maximal concentration.
a n = 53 for C24h, n = 49 for C8h.
b n = 29 for C8h.
c One subject in the group did not have sufficient points for AUC8h due to being below the lower limit of quantification; AUC last was used.
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EFV; 3.5- and 3.3-fold, respectively, for NVP). DHAAUC0–8h was
reduced by 3.4-fold with EFV and approached signiﬁcance with
NVP. Cmax was only reduced (2.8-fold) in the context of EFV.
In contrast, LPV/r did not impact artemisinin parameters.
Comparisons between ART groups (ratios not shown) revealed
that EFV and NVP were associated with lower artemether
AUC0–8h compared with LPV/r (reduced 1.9-fold [P = .0096])
and 2.5-fold [P = .0001], respectively). For DHA, AUC0–8h
was reduced in children on EFV compared to children on either
LPV/r- or NVP-based ART (reduced 2.7-fold [P < .0001] and
2.2-fold [P = .0003], respectively). The DHA/artemether
AUC0–8h ratio was 2-fold higher in children on NVP compared
with all other groups (P≤ .0003 for all comparisons).
Pharmacokinetics of Lumefantrine
Pharmacokinetic parameters are summarized in Table 3 and
Figure 1. Compared with HIV-uninfected children, children
on ART demonstrated highly signiﬁcant and contrasting
Figure 1. Plasma concentration-time profile of artemether (A), dihydroartemisinin (DHA) (B), and lumefantrine (C) in human immunodeficiency virus (HIV)-uninfected
(no antiretroviral therapy [ART]) and HIV-infected children (stabilized on either an efavirenz [EFV]-, nevirapine [NVP]-, or lopinavair/ritonavir [LPV/r]–based regimen). Data
are represented as median, and values below the limit of quantitation (BLQ) are shown.
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changes in lumefantrine AUC0-∞: a 2.1-fold decrease with EFV
and 2.1-fold increase with LPV/r, but no change with NVP.
Half-life did not change with LPV/r, but was 61% shorter
with EFV compared with HIV-uninfected children
(P < .0001). Compared to HIV-uninfected children, median
day 7 lumefantrine concentrations were 3.1-fold lower in
EFV-treated and 3.4-fold higher in LPV/r-treated children
(P < .0001 for both).
Comparing lumefantrine AUC0-∞ between ART groups,
those on EFV and NVP had 4.1- and 2.0-fold lower exposure,
respectively (P < .0001 for both), and day 7 concentrations were
reduced 10.3- and 2.7-fold with EFV and NVP, respectively,
compared with LPV/r (P < .0001 for both). Finally, for children
on EFV, day 14 and 21 concentrations were markedly lower
(76% and 80% were below detection limits, respectively) com-
pared with children on NVP, LPV/r, and no ART (P≤ .0018 for
all comparisons).
Lumefantrine Exposure and Treatment Outcomes
Standardized WHO 28-day outcomes are in Table 4, and the
42-day cumulative risk of recurrent malaria for all groups is de-
picted in Figure 2 (42-day outcomes in Supplementary Data).
Using GEEs adjusted for covariates, the odds of recurrent ma-
laria in HIV-uninfected children was signiﬁcantly higher than
in children on all 3 ART regimens, differences which persisted
through day 42 (Table 5; Supplementary Table 1).
Associations between outcomes and previously deﬁned day 7
protective “thresholds” are noted in Table 5. Day 7 concentra-
tions ≥200 ng/mL or ≥175 ng/mL were associated with a 44%
and 43% reduced 28-day odds of recurrence, respectively [23–25].
Neither threshold was predictive at 42 days (Supplementary
Table 1).
Comparing outcomes between ART groups revealed that
children on EFV-based ART had a 3.7 higher odds (P = .04) of
28-day recurrence than did children on LPV/r-based ART
(Table 5). Inclusion of day 7 lumefantrine concentration into
Table 3. Lumefantrine Pharmacokinetics Following a 6-Dose Regimen of Artemether-Lumefantrine in Human Immunodeficiency Virus (HIV)-Uninfected
and HIV-Infected Children
Pharmacokinetic Parameter
HIV-Uninfected HIV-Infected Ratio (P Value)
No ART EFV LPV/r NVP EFV/No ART LPV/No ART NVP/No ART
Intensive PK arm n = 54a n = 31 n = 30 n = 30
Cmax, ng/mL, geometric
mean (90% CI)
5782 (5025–6652) 4725 (3921–5694) 8905 (7366–11 000) 6281 (5203–7582) 0.82 (.15) 1.54 (.003) 1.09 (.56)
Tmax, h 4.0 (0.0–8.0) 4.2 (0.6–8.0) 4.1 (0.0–8.1) 8.0 (0.4–8.0) 1.1 (.05) 1.0 (.43) 2.0 (.13)
T1/2, h 64.3 (52.0–120.6) 23.7 (21.8–46.0) 98.7 (88.4–119.1) 63.4 (46.8–111.1) 0.369 (<.0001) 1.54 (.13) 0.988 (.51)
AUC0-∞, h × ug/mL,
geometric mean
(90% CI)
270 (232–313) 130 (107–157) 579 (477–704) 278 (228–339) 0.48 (<.0001) 2.14 (<.0001) 1.03 (.84)
Intensive + sparse
sampling PK arms
n = 186b n = 48c n = 70d n = 62e
C7d, ng/mL 340 (257–531) 111 (63–192) 1140 (515–2220) 426 (282–733) 0.30 (<.0001) 3.4 (<.0001) 1.3 (.13)
C14d, ng/mL 86 (59–137) BLQ (BLQ–BLQ) 323 (174–584) 115 (68–178) <1 (<.0001) 3.8 (<.0001) 1.3 (.05)
C21d, ng/mL BLQ (BLQ–63) BLQ (BLQ–BLQ) 159 (81–275) BLQ (BLQ–83) (.002) >1 (<.0001) (.28)
Data are presented as median (interquartile range) unless otherwise specified. Significance level: α = .0083. All comparisons made using mixed-models repeated measures analysis of log-
transformed values.
Abbreviations: ART, antiretroviral therapy; AUC, area under the concentration-time curve; BLQ, below the limit of quantitation; CI, confidence interval; Cmax, maximal concentration; EFV, efavirenz;
HIV, human immunodeficiency virus; LPV, lopinavir; NVP, nevirapine; PK, pharmacokinetics; r, ritonavir; T1/2, elimination half-life; Tmax, time to maximal concentration.
a n = 52 for T1/2 and AUC.
b n = 183 (C14d) and 176 (C21d).
c n = 46 (C14d) and 44 (C21d).
d n = 65 (C14d and C21d).
e n = 60 (C14d) and 59 (C21d).
Table 4. World Health Organization 28-Day Treatment Outcomes
Stratified by Antiretroviral Therapy Group
Outcome
Day 28 Outcomesa
HIV-
Uninfected
Children
(n = 181)b
HIV-Infected Children
EFV-
Based
ART
(n = 50)
LPV/r-
Based
ART
(n = 70)
NVP-
Based
ART
(n = 61)
Adequate clinical and
parasitological response
51.4 (93) 62.0 (31) 85.7 (60) 68.9 (42)
Late parasitological failure 39.2 (71) 30.0 (15) 14.3 (10) 19.7 (12)
Late clinical failure 9.4 (17) 8.0 (4) 0 (0) 11.5 (7)
Data are presented as percentage (No.) with polymerase chain reaction–unadjusted
treatment outcome.
Abbreviations: ART, antiretroviral therapy; EFV, efavirenz; HIV, human immunodeficiency
virus; LPV/r, lopinavir/ritonavir; NVP, nevirapine.
a Eight children not included in World Health Organization day 28 outcomes analysis due to
taking other antimalarials over the course of follow-up and lost to follow-up. One child died
due to pneumonia on day 23.
b Significant differences (P < .05) in any treatment failure (late parasitological failure + late
clinical failure) outcome between LPV/r-treated children and both the HIV-uninfected and
EFV-treated children.
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the model resulted in a reduction in odds ratio (OR) to 1.8 and
loss of statistical signiﬁcance. Formal mediation analysis
indicated that 60% of the difference at day 28 between the EFV
and LPV/r groups was attributable to differences in day 7 lume-
fantrine concentrations (median, 111 vs 1140 ng/mL; P < .0001).
Similarly, 27% of the effect of LPV/r-based ART vs no ART was
attributable to day 7 concentrations; both 28-day mediation ef-
fects were signiﬁcant (P = .005, P < .0001, respectively). Similar
42-day mediation effects were not observed.
In the intensive cohort, lumefantrine day 7 concentrations
were highly correlated with AUC (Pearson r = 0.87; P < .0001).
In a GEE analysis for this smaller intensive cohort, the odds of
28-day recurrence were not associated with lumefantrine day 7
concentration (OR, 0.91; 95% conﬁdence interval [CI], .70–
1.17; P = .46), while the odds of recurrence was signiﬁcantly as-
sociated with lumefantrine AUC (OR, 0.61; 95% CI, .38–.96;
P = .03). Neither parameter was a signiﬁcant predictor of 42-
day outcomes in this smaller cohort.
Treatment Outcomes Adjusted for Genotyping
Ninety-six percent of recurrent malaria episodes were geno-
typed with 11 cases of recrudescence by day 28 (8.5%), but
there was no difference in distribution based on age, HIV status,
or ART (3 NVP, 2 LPV/r, 1 EFV, and 5 HIV-uninfected). Lower
day 7 concentrations were seen in recrudescent infections (224
ng/mL) compared with adequate clinical and parasitological re-
sponse (ACPR) (421 ng/mL) (P = .008). Lower day 14 lumefan-
trine concentrations were seen in recrudescent (62 ng/mL)
compared with both new infections and ACPR (80 ng/mL
[P = .02] and 115 ng/mL [P = .002], respectively).
Safety and Tolerability of Artemether-Lumefantrine
Artemether-lumefantrine was well tolerated throughout the
study with <20 cases of grade 3 laboratory abnormalities in
the context of 366 episodes of malaria (eg, reduced platelet
or neutrophil count) that were independent of study arm.
Table 5. Generalized Estimating Equation Logistic Regression on Recurrent Malaria by Day 28
Variables
Recurrent Malaria by Day 28
Unadjusted OR
(95% CI) P Value
Adjusted OR Without
LR Day 7 (95% CI) P Value
Adjusted OR With
LR Day 7 (95% CI) P Value
LPV/r Reference
EFV 3.38 (1.01–11.35) .049 3.74 (1.02–13.74) .04 1.77 (.36–8.81) .48
NVP 2.68 (.84–8.56) .10 2.86 (.85–9.60) .09 2.26 (.64–8.05) .21
HIV-uninfected 6.32 (2.23–17.95) .0005 6.48 (2.18–19.21) .0008 5.03 (1.58–15.98) .006
NVP Reference
EFV 1.26 (.5–3.17) .62 1.31 (.49–3.51) .59 0.78 (.32–2.37) .66
HIV-uninfected 2.36 (1.21–4.58) .01 2.27 (1.12–4.60) .02 2.22 (1.10–4.48) .03
EFV Reference
HIV-uninfected 1.87 (.86–4.06) .11 1.73 (.73–4.11) .21 2.84 (1.04–7.78) .04
Parasite density at baseline, log 1.12 (1.01–1.24) .03 1.04 (.92–1.18) .53 1.03 (.91–1.18) .61
Hb at baseline, g/dL 0.82 (.69–.97) .02 0.82 (.68–1.00) .05 0.82 (.67–.99) .04
Age, y 0.81 (.7–.95) .008 0.90 (.76–1.07) .22 0.92 (.77–1.10) .36
LR level at day 7 in ng/mLa 0.73 (.58–.92) .008 0.75 (.58–.96) .02
LR day 7≥ 200 ng/mL 0.56 (.34–.92) .02
LR day 7≥ 175 ng/mL 0.57 (.33–.97) .04
LR day 7≥ 280 ng/mL 0.65 (.41–1.02) .06
Abbreviations: CI, confidence interval; EFV, efavirenz; Hb, hemoglobin; HIV, human immunodeficiency virus; LPV/r, lopinavir/ritonavir; LR, lumefantrine; NVP, nevirapine; OR, odds ratio.
a Natural log-transformed lumefantrine concentration on day 7.
Figure 2. Cumulative risk of recurrent malaria by day 42 following treatment with
artemether-lumefantrine stratified by human immunodeficiency virus (HIV) status
and antiretroviral therapy regimen. Includes children from intensive and sparse co-
horts. Risk-adjusted for repeated measures, age, parasite density, and hemoglobin
on day 0. Abbreviations: EFV, efavirenz; LPV/r, lopinavir/ritonavir; NVP, nevirapine.
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Abnormalities were followed until grade 2 or lower and were
largely attributed to HIV, ART, or malarial infection.
DISCUSSION
For HIV-infected children requiring treatment of uncomplicat-
ed P. falciparum malaria with artemether-lumefantrine, selec-
tion of ART has a highly signiﬁcant impact on antimalarial
PK exposure and clinical outcomes. We compared PK exposure
of artemether-lumefantrine in HIV-infected children on 3 ﬁrst-
line ART regimens to HIV-uninfected children, demonstrating
that EFV-based ART results in 2.1- to 3.4-fold reductions in the
AUC of artemether, DHA, and lumefantrine. In contrast, LPV/
r-based ART had the opposite impact on lumefantrine expo-
sure, increasing the AUC by 2.1-fold, and had no impact on
the artemisinins, while the use of NVP-based ART signiﬁcantly
reduced exposure to artemether only. Comparisons of day 7 lu-
mefantrine concentrations between ART groups revealed that
concentrations were approximately 10-fold and 3-fold lower
in children on EFV and NVP, respectively, compared with chil-
dren on LPV/r. AUC, a more robust PK parameter of exposure,
differed signiﬁcantly between groups as well.
Differences in exposure to lumefantrine played a critical role
in determining treatment outcomes. The risk of recurrent ma-
laria differed signiﬁcantly between EFV- and LPV/r-based ART,
with those on EFV exhibiting a nearly 4-fold higher 28-day
odds of recurrent malaria. Mediation analysis demonstrated
that the increased 28-day risk was driven largely by lower lume-
fantrine exposure in those on EFV. This effect was not evident
at 42 days, which may reﬂect that lumefantrine concentrations
in all individuals are below a protective threshold by day 42,
leaving them equally at risk of new infections in this high-trans-
mission region. We conﬁrmed that concentrations of >175 and
>200 ng/mL were predictive of 28-day recurrent malaria; chil-
dren exceeding these values had approximately 44% lower
risk of recurrence. We also demonstrated that those with recur-
rence compared to ACPR had lower median lumefantrine con-
centrations [4, 23–25]. Interestingly, in the intensive cohort,
AUC was a stronger predictor of outcomes than day 7 concen-
tration. A 1-natural-log increase in AUC yielded a 40% decrease
in the 28-day odds of recurrence (P = .03), while day 7 concen-
tration in this smaller group of children was not a signiﬁcant
predictor, underscoring the important information generated
by the intensive PK design.
ART also variably altered artemisinin PK. Compared with
HIV-uninfected controls, EFV and NVP reduced the AUC0–
8h of artemether and DHA up to 3.5-fold, LPV/r had no effect,
and NVP increased artemether to DHA conversion by 2-fold;
these are differences that may impact outcomes and/or selective
pressure for artemisinin resistance, although our study did not
assess these associations. Differences in how each ART impacts
artemether or lumefantrine PK are attributed to varying effects
on CYP3A4, whereas changes for DHA may be due to altered
uridine glucuronosyltransferase activity [13, 26, 27].
EFV-based ART is ﬁrst-line for all children >3 years of age,
including adolescents, adults, and pregnant/breastfeeding
women. Because EFV reduces exposure to all 3 antimalarial
components and increases the risk of recurrent malaria, close
clinical follow-up of artemether-lumefantrine–treated children
on EFV is necessary. In addition, underexposure may increase
the risk for the selection and spread of ACT-resistant parasites,
such as was seen following the systematic underdosing of sulfa-
doxine-pyrimethamine in children [13, 28]. In our study, true
recrudescence was documented in 9% of recurrent infections,
and although there were no risk differences in recrudescence be-
tween ART groups, day 14 lumefantrine concentrations were
signiﬁcantly lower in children with recrudescence vs new infec-
tions. With the independent emergence and spread of ACT re-
sistance in Asia, and the selection for resistance-mediating
mutations in Africa, ensuring optimal ACT dosing for the
large numbers of HIV/malaria-coinfected individuals on
EFV-based ART is critical [13, 29–32]. The study of modiﬁed
dosing regimens of artemether-lumefantrine, such as extension
of dosing to 5 days in the setting of EFV, is urgently needed,
sentiments supported by others [33, 34]. In contrast, LPV/r ap-
pears to be protective against recurrent malaria, and our group
and others have demonstrated that LPV/r has in vitro and pos-
sible in vivo direct antimalarial effects [4, 35–40]. The use of
LPV/r is predicted to avert 278–1043 annual incidences of
Figure 3. Cumulative risk of recurrent malaria by day 42 following treatment with
artemether-lumefantrine stratified by human immunodeficiency virus (HIV) status
and a day 7 lumefantrine concentration of 200 ng/mL. Includes children from inten-
sive and sparse cohorts. Risk-adjusted for repeated measures, age, parasite density,
and hemoglobin on day 0.
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malaria per 1000 children compared to NNRTI-based regimens
in varied sub-Saharan settings [9, 41–43].
In addition to the effects of ART, the use of TMP-SMX re-
duces one’s risk of malaria [11, 44]. Ninety-six percent of our
HIV-infected participants were on TMP-SMX, as recommend-
ed for all HIV-infected children by the WHO [8]. Indeed, HIV-
infected children had a lower overall risk of recurrent malaria
compared with HIV-uninfected children in our study, a differ-
ence that was evident even when lumefantrine exposure was
similar (ie, for NVP-treated and HIV-uninfected children).
Overall, our results underscore the beneﬁts of daily TMP-
SMX prophylaxis and ﬁrst-line ART in reducing malaria mor-
bidity in HIV-infected individuals compared with that seen in
the pre-ART and pre-TMP-SMX eras [8, 10].
Artemether-lumefantrine and ART interactions have
previously been studied, but few studies linked intensive PK
with malaria clinical outcomes, and none were in children
[33, 45–48]. Day 7 concentrations with EFV, but not LPV/r,
were collected in Tanzanian adults, and demonstrated a >19-
fold higher risk of recurrence in EFV-treated compared with
HIV-infected adults not on ART [45]. PK studies from HIV-
infected Ugandan adults reported similar effects of ART on
terminal lumefantrine concentrations, although sample sizes
were substantially smaller, sampling duration was shorter,
subjects were not malaria infected, and no PK/PD associations
were possible [33, 46–48]. Our own group initially studied
antimalarial–ART interactions in healthy adults; however,
the impact of EFV on artemether-lumefantrine was under-
estimated by >50%, emphasizing the value of conducting stud-
ies directly in the most relevant populations, particularly
children who exhibit PK distinctions and higher risks of
malaria [49–54].
In summary, our results demonstrate that the selection of
ﬁrst-line ART has extensive effects on PK exposure of the
most widely adopted ACT, artemether-lumefantrine. Children
on EFV-based ART had highly signiﬁcant reductions in expo-
sure to all 3 antimalarial components, and, compared with chil-
dren on LPV/r-based ART, experienced higher rates of
recurrent malaria. In 2014, 86% of the 58 WHO focus countries
adopted EFV-based ART as the preferred ﬁrst-line regimen,
which will be widely used to treat the estimated 25 million
ART-eligible individuals in sub-Saharan Africa [7, 9, 55]. Use
of artemether-lumefantrine at standard doses for treating ma-
laria in the context of EFV may enhance the emergence and se-
lection of ACT-resistant parasites and, therefore, study of
modiﬁed dosing regimens such as an extended duration of
artemether-lumefantrine in this setting is urgently needed.
Until data on a modiﬁed artemether-lumefantrine dosing regi-
men is available, we advise close clinical follow-up for recurrent
malaria following treatment with artemether-lumefantrine in
the setting of EFV-based ART. In contrast, use of artemether-
lumefantrine with LPV/r-based ART in this study led to
pronounced increases in lumefantrine exposure with no change
in artemisinin exposure, and therefore provides further evi-
dence that LPV/r-based ART provides important beneﬁts for
treating malaria in endemic regions [43].
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